CAR-T Cell Therapy Insurance Denied? How to Appeal

CAR-T (chimeric antigen receptor T-cell) therapy is FDA-approved for specific blood cancers and represents one of the most significant advances in cancer treatment in decades. The FDA has approved multiple CAR-T products — Kymriah, Yescarta, Breyanzi, Abecma, Carvykti, and Tecartus — each for specific hematologic malignancies and prior treatment line requirements. Yet insurers routinely deny coverage for these FDA-approved therapies at costs of $373,000–$475,000 per infusion, leaving patients with aggressive cancers fighting their insurance company while fighting for their lives. CAR-T denials are among the most legally and clinically indefensible coverage decisions insurers issue.

Why Insurers Deny CAR-T Cell Therapy

Understanding the specific denial reason shapes your entire appeal strategy.

• "Experimental or investigational": Despite full FDA approval, some insurers classify CAR-T therapy as experimental — particularly for recently approved indications. For FDA-approved products used within their approved indications, this classification is factually wrong and legally indefensible.
• "Prior therapy line count not met": Most CAR-T products are approved for relapsed or refractory disease after a specific number of prior treatment lines. Insurers may deny by claiming the documented line count is insufficient. Clear documentation of every prior regimen is essential.
• "Out-of-network facility": CAR-T therapy is only available at FACT-accredited cancer centers. If none is in-network, the insurer may deny on network grounds even when no in-network facility offers the treatment.
• "Not medically necessary": The insurer argues that the patient's disease state, performance status, or comorbidities make CAR-T unlikely to succeed by applying internal criteria that may be more restrictive than FDA labeling.
• "Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization failures": CAR-T requires extensive PA with specific clinical documentation. Denials may cite that required documentation was incomplete.
• Cost-driven utilization management: The financial incentive to deny at these cost levels is significant, and denial criteria are sometimes applied more stringently than the clinical evidence warrants.

How to Appeal a CAR-T Cell Therapy Denial

Step 1: Invoke Expedited Review Immediately

Cancer does not wait for standard appeal timelines. Under ACA regulations (45 CFR § 147.136) and ERISA (29 CFR § 2560.503-1), you are entitled to a 72-hour expedited decision when delay would jeopardize your health. For CAR-T specifically, the 3–6 week manufacturing lead time means delays compound urgency exponentially — state this explicitly in your expedited review request. Every day of delay potentially affects treatment feasibility.

Step 2: Engage Your Oncologist and the CAR-T Center's Insurance Team

Major cancer centers offering CAR-T have dedicated insurance authorization teams with deep experience fighting these specific denials. Engage them immediately — they have the clinical documentation templates, precedent cases, and direct lines to insurer medical directors that individual appeals lack. Your oncologist should simultaneously request a peer-to-peer review with the insurer's medical director.

Step 3: Address the "Experimental" Argument With Specific FDA Documentation

If the denial is based on experimental classification, your appeal must include the FDA approval documentation for the specific CAR-T product and your exact indication, the FDA-approved prescribing information showing your cancer type and prior line requirements, the NCCN guideline recommendation (CAR-T is included in NCCN guidelines for specific lymphomas, leukemias, and multiple myeloma at Category 1 or 2A evidence levels), and published clinical trial data — ZUMA-1 (Yescarta), JULIET (Kymriah), TRANSCEND (Breyanzi), KarMMa (Abecma), CARTITUDE-1 (Carvykti), ZUMA-2 (Tecartus) as applicable. An insurer denying FDA-approved treatment as experimental must overcome all of this evidence simultaneously.

Step 4: Document Prior Therapy Lines Comprehensively

List every prior treatment line with dates, specific regimens, documented responses or progression (using RECIST criteria or hematologic response criteria), and the specific reason for discontinuation (progression versus toxicity). This documentation directly addresses the most common technical CAR-T denial — insufficient prior line count. Each line must be distinguishable as a separate therapeutic attempt with its own start date, end date, regimen, and clinical outcome.

Step 5: Address Network Adequacy if the Denial Is Network-Based

If no in-network facility offers CAR-T therapy for your specific cancer type, document this specifically and request authorization at the nearest FACT-accredited CAR-T center at in-network cost-sharing under your plan's network adequacy provisions. Most state insurance codes and ACA regulations require plans to authorize out-of-network care when no in-network provider can deliver the required service.

Step 6: Submit the Internal Appeal and Escalate

Submit all supporting documentation via certified mail and the insurer's portal. If the internal appeal fails, file for External Independent Review: Complete Guide" class="auto-link">external review immediately requesting an oncology-specialized reviewer. File a complaint with your state's Department of Insurance. For ERISA employer-sponsored plans, file a complaint with the Department of Labor's Employee Benefits Security Administration.

What to Include in Your Appeal

• Denial letter with reason codes and policy provision citations
• FDA approval documentation for the specific CAR-T product (Kymriah, Yescarta, Breyanzi, Abecma, Carvykti, or Tecartus) and your exact indication
• NCCN Clinical Practice Guideline showing CAR-T as a recommended therapy for your cancer type and line of therapy
• Complete prior treatment history: every treatment line with dates, specific regimens, response data, and documented failure or discontinuation reason
• Pathology and molecular testing confirming diagnosis and required markers (CD19 positivity for Kymriah/Yescarta; BCMA expression for multiple myeloma products)
• Staging imaging and disease status documentation
• Oncologist's letter of medical necessity explaining why CAR-T is the appropriate next treatment for this specific patient
• ECOG performance status documentation
• Letter from the CAR-T center confirming patient acceptance for treatment
• Peer-reviewed publications from the pivotal clinical trials for your specific cancer type
• Network adequacy documentation if seeking authorization at an out-of-network FACT-accredited center

Fight Back With ClaimBack

CAR-T denials are urgent and require appeals that combine FDA approval evidence, NCCN guideline citations, detailed prior therapy documentation, and the clinical urgency of manufacturing timelines. Time is not a formality — it is a clinical reality. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal